BeiGene
BGNE
#990
Rank
S$26.75 B
Marketcap
$241.86
Share price
1.55%
Change (1 day)
-0.57%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -$22.80

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -$22.48. In 2022 the company made an earnings per share (EPS) of -$26.16 a decrease over its 2021 EPS that were of -$20.54.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$22.80-12.84%
2022-$26.1627.35%
2021-$20.54-19.96%
2020-$25.6720.81%
2019-$21.2531.52%
2018-$16.15417.57%
2017-$3.12-37.16%
2016-$4.97158.95%
2015-$1.92

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$1.35-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.36-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA